Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

被引：0
|
作者：
She, Q.-B.
Chandarlapaty, S.
Ye, Q.
Lobo, J.
Haskell, K. M.
Leander, K. R.
DeFeo-Jones, D.
Huber, H. E.
Rosen, N.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Merck Res Labs, West Point, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [21] PIK3CA, AKT1 MUTATION AND HER2 AMPLIFICATION GENE SIGNATURES (GS) SUGGEST PREDOMINANTLY NEGATIVE FEEDBACK INHIBITION OF PI3K/AKT PATHWAY IN HUMAN BREAST CANCER (BC).
    Loi, S.
    Haibe-Kains, B.
    Lallemand, F.
    Pusztai, L.
    Tutt, A.
    Gillett, C. E.
    Piccart, M.
    Phillips, W. A.
    McArthur, G.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2009, 20 : 45 - 45
  • [22] Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
    Kallergi, Galatea
    Agelaki, Sofia
    Kalykaki, Antonia
    Stournaras, Christos
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    BREAST CANCER RESEARCH, 2008, 10 (05)
  • [23] Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
    Galatea Kallergi
    Sofia Agelaki
    Antonia Kalykaki
    Christos Stournaras
    Dimitris Mavroudis
    Vassilis Georgoulias
    Breast Cancer Research, 10
  • [24] Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy
    O'Brien, Neil
    Browne, Brigid
    Chow, Lucy
    Ginther, Charles
    Bensadigh, Brian
    Atefi, Mohammad
    Arboleda, Jane
    Duffy, Michael
    Crown, John
    O'Donovan, Norma
    Slamon, Dennis
    CANCER RESEARCH, 2009, 69
  • [25] HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
    Christiane Knuefermann
    Yang Lu
    Bolin Liu
    Weidong Jin
    Ke Liang
    Ling Wu
    Mathias Schmidt
    Gordon B Mills
    John Mendelsohn
    Zhen Fan
    Oncogene, 2003, 22 : 3205 - 3212
  • [26] PI3K/Akt signaling in osteosarcoma
    Zhang, Jian
    Yu, Xiao-Hua
    Yan, Yi-Guo
    Wang, Cheng
    Wang, Wen-Jun
    CLINICA CHIMICA ACTA, 2015, 444 : 182 - 192
  • [27] HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
    Knuefermann, C
    Lu, Y
    Liu, BL
    Jin, WD
    Liang, K
    Wu, L
    Schmidt, M
    Mills, GB
    Mendelsohn, J
    Fan, Z
    ONCOGENE, 2003, 22 (21) : 3205 - 3212
  • [28] PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells
    Navaei, Zahra Nasrpour
    Khalili-Tanha, Ghazaleh
    Zangouei, Amir Sadra
    Abbaszadegan, Mohammad Reza
    Moghbeli, Meysam
    ONCOLOGY RESEARCH, 2021, 29 (04) : 235 - 250
  • [29] HER2 amplification is associated with higher tumor mutation burden in breast cancer
    Yin, Y.
    Li, W.
    Huang, X.
    Wu, H.
    Zhang, Y.
    Cai, S.
    Zhou, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Divergent activation of AKT1 and AKT2 isoforms downstream of PI3K mutation impacts response of breast cancer cells to estradiol and PI3K inhibitors
    Nakshatri, Harikrishna
    Goswami, Chirayu
    Badve, Sunil
    Magnani, Luca
    Lupien, Mathieu
    Bhat-Nakshatri, Poornima
    CANCER RESEARCH, 2015, 75
12345